Issue link: https://www.e-digitaleditions.com/i/1521797
18 June 2024 Inhalation 22. T. F. Bahamondez-Canas and Z. Cui, Intrana- sal immunization with dry powder vaccines, Eur J Pharm Biopharm, vol. 122, 2018, doi: 10.1016/j. ejpb.2017.11.001. 23. D. Per Gisle and H. Roderick Peter, Nasal admin- istration, 2008, https://patents.google.com/patent/ WO2008122795A2/en. 24. S. Hufnagel, S. Sahakijpijarn, C. Moon, Z. Cui, and R. O. Williams III, e development of thin- film freezing and its application to improve delivery of biologics as dry powder aerosols, KONA Powder Part J, vol. 39, pp. 176-192, 2022, doi: 10.14356/ kona.2022010. 25. Y. S. Yu, K. AboulFotouh, H. Xu, G. Williams, J. Suman, C. Cano, Z. N. Warnken, K. C. Wu, R. O. Williams III, Z. Cui, Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine pow- ders, Int J Pharm, vol. 640, 2023, doi: 10.1016/j. ijpharm.2023.122990. 26. Y. S. Yu, H. Xu, K. AboulFotouh, G. Williams, J. Suman, S. Sahakijpijarn, C. Cano, Z. N. Warnken, K. C. W. Wu, R. O. Williams III, Z Cui, Feasibility of intranasal delivery of thin-film freeze-dried mono- clonal antibodies, bioRxiv, p. 2023.10.23.563139, Jan. 2023, doi: 10.1101/2023.10.23.563139. 27. L. Salade, N. Wauthoz, J. Goole, and K. Amighi, How to characterize a nasal product. e state of the art of in vitro and ex vivo specific meth- ods, Int J Pharm, vol. 561, 2019, doi: 10.1016/j. ijpharm.2019.02.026. 28. A. Hafner, Advances in Development, Char- acterisation and application of nasal drug delivery systems, Pharmaceutics, vol. 14, no. 8, 2022, doi: 10.3390/pharmaceutics14081562. 29. M. Trenkel and R. Scherließ, Nasal powder for- mulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects, Pharmaceutics, vol. 13, no. 3, 2021, doi: 10.3390/ pharmaceutics13030385. 30. A. Abdelkawi, J. P. Perez Martinez, and Y. V. Pathak, Is ere a Global Market and Opportunities for Nasal Drug Delivery? Recent Trends in Global Nasal Delivery Market, in Nasal Drug Delivery, Cham: Springer International Publishing, 2023, pp. 381-392. doi: 10.1007/978-3-031-23112-4_18. 31. FDA approves first treatment for severe hypogly- cemia that can be administered without an injection, FDA News Release. Jan. 10, 2024. [Online]. https:// www.fda.gov/news-events/press-announcements /fda-approves-first-treatment-severe-hypoglyce mia-can-be-administered-without-injection. 32. S. Sawarkar and J. Suman, Nasal Drug Delivery System: Regulatory Perspective, in Nasal Drug Deliv- ery, Cham: Springer International Publishing, 2023, pp. 393-416. doi: 10.1007/978-3-031-23112-4_19. 12. Y. Tal, Y. Ribak, L. Rubin, A. Talmon, O. Sham- riz, A. Y. Hershko, S. Blotnick, M. Bouhajib, G.T. Krayz, C. Abrutzky, D. Megiddo, T. Lapidot and Y. Caraco, Fast acting, dry powder, needle-free, intrana- sal epinephrine spray: A promising future treatment for anaphylaxis, JACI: In Practice, vol. 11, no. 10, 2023, doi: 10.1016/j.jaip.2023.06.044. 13. J. A. Lieberman, J. Oppenheimer, V. P. Her- nandez-Trujillo and M. S. Blaiss, Innovations in the treatment of anaphylaxis: A review of recent data, Ann Allergy, Asthma Immunol, vol. 131, no. 2, 2023, doi: 10.1016/j.anai.2023.05.033. 14. P. Henriques, A. Fortuna and S. Doktorovová, Spray dried powders for nasal delivery: Process and formulation considerations, Eur J Pharm Biopharm, vol. 176, 2022, doi: 10.1016/j.ejpb.2022.05.002. 15. D. A. Miller and M. Gil, Spray-Drying Technol- ogy, in Formulating Poorly Water Soluble Drugs, R. O. Williams III, A. B. Watts, and D. A. Miller, Eds., New York, NY: Springer New York, 2012, pp. 363- 442. doi: 10.1007/978-1-4614-1144-4_10. 16. P. Henriques, J. Bicker, A. Carona, M. Miranda, C. Vitorino, S. Doktorovová and A. Fortuna, Amor- phous nasal powder advanced performance: In vitro/ ex vivo studies and correlation with in vivo pharma- cokinetics, J Pharm Investig, vol. 53, no. 5, 2023, doi: 10.1007/s40005-023-00630-1. 17. R. Rashid, D. W. Kim, F. U. Din, O. Musta- pha, A. M. Yousaf, J. H. Park, J. O. Kim, C. S. Yong and H. G. Choi, Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion, Carbohydr Polym, vol. 130, pp. 26-31, 2015, doi: 10.1016/j.carbpol.2015.04.071. 18. A. D. Brunaugh, L. Ding, T. Wu, M. Schnei- der, R. Khalaf, and H. D. C. Smyth, Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder, J Pharm Sci, vol. 111, no. 2, 2022, doi: 10.1016/j. xphs.2021.08.022. 19. S. S. Davis and L. Illum, Absorption en- hancers for nasal drug delivery, Clinical Phar- m ac ok i net ic s, vol. 4 2 , no. 13, 20 03, doi: 10.2165/00003088-200342130-00003. 20. A. Giuliani, A. G. Balducci, E. Zironi, G. Colombo, F. Bortolotti, L. Lorenzini, V. Galli- gioni, G. Pagliuca, A. Scagliarini, L. Calzà and F. Sonvico, In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates, Drug Deliv, vol. 25, no. 1, 2018, doi: 10.1080/10717544.2018.1428242. 21. D. T. Osanlóo, J. Fransson, B. Bergenståhl, and A. Millqvist-Fureby, Effects of drying methods on phys- ical properties and morphology of trehalose/mannitol mixtures, Dry Technol, vol. 41, no. 4, pp. 503-522, Mar. 2023, doi: 10.1080/07373937.2022.2103564.